S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

IDEAYA Biosciences Stock Forecast, Price & News

+0.52 (+3.77%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
151,771 shs
Average Volume
342,711 shs
Market Capitalization
$553.32 million
P/E Ratio
Dividend Yield
Price Target

IDEAYA Biosciences Stock Forecast (MarketRank)

Analyst Rating
3.00 Rating Score
127.0% Upside
$32.50 Price Target
Short Interest
13.38% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.22mentions of IDEAYA Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.73) to ($2.44) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.30 out of 5 stars

Medical Sector

663rd out of 1,429 stocks

Pharmaceutical Preparations Industry

313th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDEAYA Biosciences logo

About IDEAYA Biosciences (NASDAQ:IDYA)

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-49.76 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$27.94 million
Book Value
$7.83 per share


Free Float
Market Cap
$553.32 million
Not Optionable

IDEAYA Biosciences Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDEAYA Biosciences stock.
View analyst ratings for IDEAYA Biosciences
or view top-rated stocks.

What is IDEAYA Biosciences' stock price forecast for 2022?

4 analysts have issued twelve-month price objectives for IDEAYA Biosciences' shares. Their IDYA stock forecasts range from $20.00 to $46.00. On average, they expect IDEAYA Biosciences' stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences
or view top-rated stocks among Wall Street analysts.

How has IDEAYA Biosciences' stock price performed in 2022?

IDEAYA Biosciences' stock was trading at $23.64 at the beginning of the year. Since then, IDYA shares have decreased by 39.4% and is now trading at $14.32.
View the best growth stocks for 2022 here

When is IDEAYA Biosciences' next earnings date?

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for IDEAYA Biosciences

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its earnings results on Tuesday, May, 10th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05. The business earned $11.36 million during the quarter, compared to the consensus estimate of $8.50 million. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 19.08% and a negative net margin of 170.82%.
View IDEAYA Biosciences' earnings history

Who are IDEAYA Biosciences' key executives?

IDEAYA Biosciences' management team includes the following people:
  • Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 48, Pay $798.72k)
  • Mr. Paul A. Stone, Sr. VP, CFO & Principal Accounting Officer (Age 58, Pay $551.44k) (LinkedIn Profile)
  • Dr. Michael A. White Ph.D., Sr. VP & Chief Scientific Officer (Age 57, Pay $261k)
  • Dr. Jeffrey Hager Ph.D., Co-Founder & Member of the Scientific Advisory Board (Age 57)
  • Mr. Andres Ruiz Briseno CPA, VP and Head of Bus. Operations & IR (Age 35)
  • Mr. Jason S. Throne J.D., Esq., Sr. VP, Gen. Counsel & Company Sec. (Age 50)
  • Dr. Mark Lackner Ph.D., Sr. VP and Head of Biology & Translational Sciences (Age 54)
  • Dr. Paul A. Barsanti Ph.D., Sr. VP & Head of Drug Discovery
  • Dr. Matthew Maurer M.D., VP and Head of Medical Affairs & Clinical Oncology
  • Mr. Mick O'Quigley, Sr. VP of Devel. Operations

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $14.32.

How much money does IDEAYA Biosciences make?

IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $553.32 million and generates $27.94 million in revenue each year. The company earns $-49.76 million in net income (profit) each year or ($1.470010) on an earnings per share basis.

How many employees does IDEAYA Biosciences have?

IDEAYA Biosciences employs 81 workers across the globe.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for IDEAYA Biosciences is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at [email protected].

This page (NASDAQ:IDYA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.